News STGI.(InternetWire) Investors' Alert Announces Investment Opinion On Steroidogenesi
Investors' Alert Announces Investment Opinion On Steroidogenesis
Inhibitors International With A 6-Month Target Of 9.00
HOUSTON, TX -- (INTERNET WIRE) -- 07/27/00 -- Investors' Alert
announces Strong Buy on Steroidogenesis Inhibitors International (OTC
BB: STGI).
Investors' Alert editor-in-chief, stated, "Could you imagine finding an
affordable treatment for AIDS that would be non-toxic and have no
side effects, one that prevents HIV-positive patients from ever
acquiring AIDS their entire life, thereby living a normal life-span
just like everyone else. Steroidogenesis Inhibitors Intl. and the
doctors who run the company believe they have just that treatment
What is the true value of this treatment? We hesitate to even guess.
How high would the stock go?
This stock has been as high as $15.00, and we here at Investors' Alert
believe this could be one of the biggest winners we have ever been
involved with. Here are the highlights."
Investors' Alert when on to state, "STGI is a pharmaceutical company
with its core technology being ANTICORT(TM). ANTICORT(TM) is
currently in FDA Phase 1B/2A clinical trials as an anticortisol drug
for the treatment of HIV positives. We interviewed Dr. Janet
Greeson, the company's president, and learned that ANTICORT(TM) is a
type of drug favored by the FDA. When tested in sixty-six AIDS
patients in Brazil, ANTICORT(TM) was shown to be effective in both
increasing the CD4 (immune cells) counts and drastically reducing the
mortality rate. This data was presented at the International AIDS
Conference in Vancouver in July of 1996.
The FDA granted an IND (IND 52,663), to STGI, to commence Phase 1B/2A
(determine safety, dosage, side effects and evaluate effectiveness)
clinical trials for the indication of AIDS, which is currently being
accomplished at the AIDS Research Alliance in West Hollywood, CA.
Dr. Greeson went on to say that the company expects FDA approval by
Sept. of next year. ANTICORT(TM) has demonstrated--in clinical
trials-that it is a non-toxic drug and is extremely effective in
both cellular testing and animal models. The company further believes
that the most compelling worldwide advantages of ANTICORT(TM) will be
its affordability and lack of side effects. STGI anticipates such
advantages will be demonstrated in its current clinical trials. As
well, STGI has had an initial discussion with the World Bank to fund
the ANTICORT(TM) needed for Africa."
Investors' Alert concluded, "In addition to this exciting drug
ANTICORT(TM), the company has the opportunity to acquire a
technology that appears to be a very important diagnostic tool in the
detection of Breast Cancer.
STGI is currently in discussions with a company that holds worldwide
patents on a novel drug-delivery system. Additionally, this product
could be a more effective delivery system for ANTICORT(TM), affording
the company a novel compound with greater bioavailability. This
company has a unique working relationship with a major university in
Texas and the Texas Medical System, and has also expressed an
interest in affording STGI the opportunity to develop a wide array of
OTC compounds.
The company is currently in the due diligence process, with the
assistance of an international investment bank, to structure a
transaction with a foreign-based company that has a portfolio of
Therapeutics, Diagnostics and Drug Delivery Systems, and almost $14
million in revenue.
Additionally, the company has signed an agreement with Josephberg Grosz
& Co., a New York-based investment bank, for a long-term
investment-banking relationship."
Symbol- STGI
Shares Outstanding - 15,444,000
Float (est.)- 4,000,000
52 Week High/Low- 2.56 - .31
6 Month Target- 9
9 Month Target- 12
Other
stocks Investors' Alert is researching, but has not made a
recommendation: Stampede Worldwide (OTC BB: STWW), Clancy Systems
International (OTC BB: CLSI), Neurotech Corp. (OTC BB: NURO),
Stereoscape.com (OTC BB: SSCP), Goldstate Corp. (OTC BB: GDSA), Titan
Motorcycles of America (NASDAQ: TMOT), USA Detergents (NASDAQ: USAD),
Tirex Corp. (OTC BB: TXMC), Archer Systems Inc. (OTC BB: ARYN), US
Electricar (OTC BB: ECAR).
Investors' Alert's most recent recommendations: Pangea Petroleum (OTC
BB: PAPO), Elite Technologies (OTC BB: ETCH).
Investors' Alert is an independent research firm with paid subscribers.
Subscriptions are $139.00/year for Investors' Alert newsletter
service. This report is based on Investors' Alert independent
analysis but relies on information supplied by sources believed to be
reliable. Access Financial Consulting has been retained to represent
STGI for a period of six months beginning July 21, 2000 and was paid
90,000 STGI restricted common shares by Pecan Tree Consulting.
Additionally, Access Financial Consulting will be paid a fee of
$39,000 by Pecan Tree Consulting for legal and other expenses
associated with this agreement. Access Financial Consulting and its
officers and directors may from time to time buy or sell common
shares in the open market or in private transactions without notice.
The information contained in this report is not intended to be, and
shall not constitute, an offer to sell nor solicitation of any offer
to buy any security; it is intended for information only. Copyright
(C) 2000 Access Financial Consulting. All rights reserved.
*** end of story *** |
